These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23480103)

  • 21. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
    Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
    Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.
    Plaza EM; Lozano ML; Guiu IS; Egea JM; Vicente V; De Terán LC; Rivera J
    Blood Transfus; 2012 Oct; 10(4):480-9. PubMed ID: 22682335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryopreservation of buffy coat-derived platelet concentrates photochemically treated with amotosalen and UVA light.
    Meinke S; Wikman A; Gryfelt G; Hultenby K; Uhlin M; Höglund P; Sandgren P
    Transfusion; 2018 Nov; 58(11):2657-2668. PubMed ID: 30281156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.
    Isola H; Kientz D; Aleil B; Laeuffer P; Weil J; Wiesel ML; Laforêt M; Lin L; Mayaudon V; Cazenave JP
    Vox Sang; 2006 Feb; 90(2):128-30. PubMed ID: 16430671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rest period does not affect in vitro storage properties in apheresis platelets collected from the buffy coat layer.
    Wagner SJ; Seetharaman S; Kurtz J
    Transfusion; 2012 Nov; 52(11):2427-31. PubMed ID: 22452313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma.
    Zhang JG; Carter CJ; Culibrk B; Devine DV; Levin E; Scammell K; Weiss S; Gyongyossy-Issa MI
    Transfusion; 2008 May; 48(5):847-56. PubMed ID: 18298601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Quality of buffy-coat-derived platelet concentrates prepared using automated system terumo automated centrifuge and separator integration (TACSI)].
    Zebrowska A; Lipska A; Rogowska A; Bujno M; Nedzi M; Radziwon P
    Pol Merkur Lekarski; 2011 Mar; 30(177):191-4. PubMed ID: 21544996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic analysis of Intercept-treated platelets.
    Prudent M; Crettaz D; Delobel J; Tissot JD; Lion N
    J Proteomics; 2012 Dec; 76 Spec No.():316-28. PubMed ID: 22813878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
    Picker SM; Steisel A; Gathof BS
    Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
    Reid S; Johnson L; Woodland N; Marks DC
    Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
    Picker SM; Tauszig ME; Gathof BS
    Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization.
    Picker SM; Speer R; Gathof BS
    Transfus Med; 2004 Jun; 14(3):217-23. PubMed ID: 15180813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters.
    Johnson L; Cameron M; Waters L; Padula MP; Marks DC
    Vox Sang; 2019 Jan; 114(1):47-56. PubMed ID: 30499111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
    Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
    Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
    Moog R; Fröhlich A; Mayaudon V; Lin L
    J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools.
    Turner CP; Sutherland J; Wadhwa M; Dilger P; Cardigan R
    Vox Sang; 2005 Apr; 88(3):164-71. PubMed ID: 15787726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.